Range Cancer Therapeutics Index ETF (CNCR)
- Previous Close
9.85 - Open
9.68 - Bid 6.98 x 200
- Ask 11.66 x 200
- Day's Range
8.96 - 9.68 - 52 Week Range
7.88 - 16.27 - Volume
4,509 - Avg. Volume
2,420 - Net Assets 7.83M
- NAV 8.97
- PE Ratio (TTM) --
- Yield 0.00%
- YTD Daily Total Return -27.21%
- Beta (5Y Monthly) 0.96
- Expense Ratio (net) 0.79%
The index was established in 2023 by Range Fund Holdings and tracks the performance of a portfolio of U.S. exchange-listed pharmaceutical or biotechnology stocks or American Depositary Receipts (“ADRs”) with a market capitalization of more than $250 million. The advisor attempts to invest all, or substantially all, of its assets in the component securities that make up the index. Under normal circumstances, at least 80% of the fund’s total assets will be invested in the component securities of the index.
Range Cancer
Fund Family
Health
Fund Category
7.83M
Net Assets
2015-10-13
Inception Date
Performance Overview: CNCR
View MoreTrailing returns as of 5/6/2025. Category is Health.
People Also Watch
Holdings: CNCR
View MoreTop 10 Holdings (18.20% of Total Assets)
Sector Weightings
Recent News: CNCR
View More
Research Reports: CNCR
View MoreDaily – Vickers Top Buyers & Sellers for 02/20/2025
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 12/05/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Alibaba Earnings: Results in Line; Shares Fairly Valued
Alibaba is the world’s largest online and mobile commerce company as measured by gross merchandise volume. It operates China’s online marketplaces, including Taobao (consumer-to-consumer) and Tmall (business-to-consumer). The China commerce retail division is the most valuable cash flow-generating business at Alibaba. Additional revenue sources include China commerce wholesale, international commerce retail/wholesale, local consumer services, cloud computing, digital media and entertainment platforms, Cainiao logistics services, and innovation initiatives/other.
RatingPrice TargetAmgen Earnings: Maintaining Our $317 Fair Value Following In-Line Quarter; Awaiting MariTide Data
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
RatingPrice Target